Hollow iron oxide nanoparticles as multidrug resistant drug delivery and imaging vehicles

Magnetic nanoparticles have been used as drug delivery vehicles against a number of cancer cells. Most of these theranostic formulations have used solid iron oxide nanoparticles (SIONPs) loaded with chemotherapeutics as nano-carrier formulation for both magnetic resonance imaging (MRI) and cancer th...

Full description

Saved in:
Bibliographic Details
Published in:Nano research 2013, Vol.6 (1), p.1-9
Main Authors: Xing, Ruijun, Bhirde, Ashwinkumar A., Wang, Shouju, Sun, Xiaolian, Liu, Gang, Hou, Yanglong, Chen, Xiaoyuan
Format: Article
Language:English
Subjects:
Atomic/Molecular Structure and Spectra
Biomedicine
Biotechnology
Cancer
Cancer therapies
Chemistry and Materials Science
Condensed Matter Physics
Dopamine
Drug delivery systems
Drugs
Formulations
Iron oxides
Load
Magnetic resonance imaging
Materials Science
Nanomaterials
Nanoparticles
Nanostructure
Nanotechnology
Particle size
Proteins
Research Article
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Magnetic nanoparticles have been used as drug delivery vehicles against a number of cancer cells. Most of these theranostic formulations have used solid iron oxide nanoparticles (SIONPs) loaded with chemotherapeutics as nano-carrier formulation for both magnetic resonance imaging (MRI) and cancer therapy. In this study, we applied the dopamine-plus-human serum albumin (HSA) method to modify hollow iron oxide nanoparticles (HIONPs) and encapsuated doxorubicin (DOX) within the hollow porous structure of the nano-carrier. The new delivery system can load more drug than solid iron oxide nanoparticles of the same core size using the same coating strategy. The HIONPs-DOX formulation also has a pH-dependent drug release behaviour. Compared with free DOX, the HIONPs-DOX were more effectively uptaken by the multidrug resistant OVCAR8-ADR cells and consequently more potent in killing drug resistant cancer cells. MRI phantom and cell studies also showed that the HIONPs-DOX can decrease the T 2 MRI signal intensity and can be used as a MRI contrast agent while acting as a drug delivery vehicle. For the first time, the dual application of chemo drug transport and MR imaging using the HIONPs-DOX formulation was achieved against both DOX-sensitive and DOX-resistant cancer cells.
ISSN:1998-0124
1998-0000
DOI:10.1007/s12274-012-0275-5